{beta}-Ray brachytherapy with {sup 106}Ru plaques for retinoblastoma

Journal Article · Sat Jul 15 00:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.02.002· OSTI ID:20849999

Schueler, Andreas O ^[1]; Fluehs, Dirk ^[2]; Anastassiou, Gerassimos ^[1]; Jurklies, Christine ^[1]; Neuhaeuser, Markus ^[3]; Schilling, Harald ^[1]; Bornfeld, Norbert ^[1]; Sauerwein, Wolfgang ^[2]

---

1. Department of Ophthalmology, Universitaetsklinikum Essen, Essen (Germany)
2. Department of Radiotherapy, Universitaetsklinikum Essen, Essen (Germany)
3. Institute for Medical Informatics, Biometry and Epidemiology, Universitaetsklinikum Essen, Essen (Germany)

Purpose: A retrospective analysis of 134 patients who received {sup 106}Ru brachytherapy for retinoblastomas (175 tumors in 140 eyes). Treatment and follow-up were analyzed with special emphasis on tumor control organ, preservation, and late complications. Results: Treated tumors had a mean height and diameter of 3.7 {+-} 1.4 mm and 5.0 {+-} 2.8 disk diameters, respectively. The radiation dose values were recalculated according to the calibration standard recently introduced by the National Institute of Standards and Technology. The recalculation revealed a mean applied dose of 419 Gy at the sclera (SD, 207 Gy) and 138 Gy (SD, 67 Gy) at the tumor apex. The 5-year tumor control rate was 94.4%. Tumor recurrence was more frequent in eyes with vitreous tumor cell seeding or fish-flesh regression. The estimated 5-year eye preservation rate was 86.5%. Previous treatment by brachytherapy or external beam radiotherapy, as well as a large tumor diameter, were significant factors for enucleation. The radiotherapy-induced complications after 5 years of follow-up were retinopathy (22%), optic neuropathy (21%), and cataract (17%). These complications were significantly more frequent after prior brachytherapy or external beam radiotherapy. Conclusion: Brachytherapy using {sup 106}Ru plaques is a highly efficient therapy with excellent local tumor control and an acceptable incidence of side effects.

• OSTI ID: 20849999
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 65, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2006.02.002; PII: S0360-3016(06)00251-3; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BEAMS
BRACHYTHERAPY
CALIBRATION STANDARDS
CATARACTS
EYES
NEOPLASMS
PATIENTS
RADIATION DOSES
RUTHENIUM 106
SIDE EFFECTS
TUMOR CELLS